Amgen (AMGN) presents positive top-line results from the Phase 3 MINT trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Goldman Sachs Reiterates Conviction Buy Rating on Amgen (AMGN)
October 16, 2024 6:02 AM EDTGoldman Sachs analyst Salveen Richter reiterated a Conviction Buy rating and $369.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "While AMGN continues to execute through a catalyst-rich year, the focus remains on key upcoming Ph2 obesity data for MariTide (GLP1-R agonistAn agonist is a drug that binds to a receptor and amplifies its intended effect./GIPR antagonist), expected by YE24, where positive results could unlock access to the obesity mega-TAM... More
